Michael Ward, MD
Sports Medicine · Hoffman Estates, ILNPI 1710953070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 428 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations.
Across 428 payments — averaging $27.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- Bayer$747
- GSK$709
- Pfizer$520
- plus $4K from 28 others
What the payments were for
- Food & beverage$11,609100%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 90 | $2,136 |
| AstraZeneca | 48 | $1,958 |
| Novo Nordisk | 51 | $1,542 |
| Bayer | 19 | $747 |
| GSK | 34 | $709 |
| Pfizer | 28 | $520 |
| Boehringer Ingelheim | 22 | $511 |
| Sanofi-aventis U.S. LLC | 22 | $499 |
| Johnson & Johnson(2 entities) | 17 | $425 |
| Corcept Therapeutics | 11 | $386 |
| Radius Health, Inc. | 9 | $344 |
| Phathom Pharmaceuticals, Inc. | 7 | $290 |
| Otsuka America Pharmaceutical, Inc. | 5 | $207 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $185 |
| Novartis | 10 | $179 |
| Exact Sciences | 7 | $174 |
| AbbVie | 2 | $142 |
| Abbott | 6 | $111 |
| Currax Pharmaceuticals LLC | 5 | $70 |
| Kowa Pharmaceuticals America, Inc. | 1 | $64 |
| Dexcom, Inc. | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Medtronic | 2 | $53 |
| Arbor Pharmaceuticals, Inc. | 4 | $51 |
| Merck | 2 | $39 |
| Phadia US Inc. | 2 | $33 |
| Embecta Corp. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Agile Therapeutics, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,645 in reported general payments places this provider in the 75th percentile of 233 sports medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 55 | $107,391 |
| OzempicSemaglutide | 62 | $95,764 |
| EliquisApixaban | 43 | $46,657 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 45 | $46,181 |
| JardianceEmpagliflozin | 28 | $38,471 |
| FarxigaDapagliflozin Propanediol | 43 | $34,199 |
| XareltoRivaroxaban | 27 | $32,346 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $30,240 |
| MounjaroTirzepatide | 24 | $29,556 |
| LinzessLinaclotide | 30 | $24,526 |
| TrulicityDulaglutide | 16 | $22,630 |
| TradjentaLinagliptin | 19 | $16,281 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,535 |
| Bydureon BciseExenatide Microspheres | 12 | $9,991 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,542 | $203,154117 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta | $511 | $100,93492 claims |
| Lilly USA, LLCMounjaro, Trulicity | $2,136 | $52,18640 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,958 | $46,73463 claims |
| PfizerEliquis | $520 | $46,65743 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $709 | $39,72540 claims |
| Johnson & JohnsonXarelto | $425 | $32,34627 claims |
| AbbVieLinzess | $142 | $24,52630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 233 sports medicine providers in Illinois.
Other sports medicine in Hoffman Estates
- Benjamin DombDes Plaines$16.3M
- Gregory NicholsonChicago$6.7M
- Grant GarriguesChicago$2.5M
- Brian ColeChicago$2.1M
- Brian ForsytheChicago$1.9M
- Nikhil VermaChicago$647K
- Shane NhoChicago$521K
- Jourdan CancienneJoliet$224K
- Vehniah TjongChicago$173K
- Aravind AthivirahamChicago$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.